Serine

Serine

SCHEMBL442652

N[C@@H](CO)C(=O)O.[N-]=[N+]=CC(=O)O

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A1 P43005 3/20 0.41
PTGS1 P23219 1/20 0.37
SLC7A11 Q9UPY5 1/20 0.37
GRIK1 P39086 8/20 0.34
GRIK2 Q13002 7/20 0.34
GRIA2 P42262 3/20 0.34
GRIA4 P48058 3/20 0.34
GRIK3 Q13003 3/20 0.34
GRIK5 Q16478 3/20 0.34
GSR P00390 2/20 0.34
GRM1 Q13255 2/20 0.34
GRM2 Q14416 2/20 0.34
GRIA1 P42261 2/20 0.34
SLC1A3 P43003 2/20 0.34
SLC1A2 P43004 2/20 0.34
SLC7A5 Q01650 1/20 0.34
GRM8 O00222 1/20 0.34
GRM6 O15303 1/20 0.34
GRIN2D O15399 1/20 0.34
GRIN3B O60391 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Serine SCHEMBL1253823 1.00 SLC1A1 (0.41) SLC1A1PTGS1SLC7A11GRIK1GRIK2
Serine SCHEMBL3185132 0.85 SLC1A1 (0.52) SLC1A1PTGS1SLC7A11GRIK1GRIK2
Serine SCHEMBL3185153 0.79 SLC1A1 (0.46) SLC1A1PTGS1SLC7A11GRIK1GRIK2
Serine SCHEMBL3185148 0.79 SLC1A1 (0.46) SLC1A1PTGS1SLC7A11GRIK1GRIK2
Serine SCHEMBL1332181 0.78
Serine SCHEMBL6520912 0.78 SLC1A1 (0.59) SLC1A1PTGS1SLC7A11GRIK1GRIK2
Serine SCHEMBL6929773 0.78 SLC1A1 (0.59) SLC1A1PTGS1SLC7A11GRIK1GRIK2
Serine SCHEMBL4455818 0.78 SLC1A1 (0.59) SLC1A1PTGS1SLC7A11GRIK1GRIK2
(D)-Serine SCHEMBL6038168 0.78 SLC1A1 (0.59) SLC1A1PTGS1SLC7A11GRIK1GRIK2
(D)-Serine SCHEMBL6660617 0.78 SLC1A1 (0.59) SLC1A1PTGS1SLC7A11GRIK1GRIK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4681778-A2 COMBINATION THERAPIES BASED ON PD1 AND IL-17B INHIBITORS Orega Biotech (FR) 2026-01-21 EP disclosed
EP-3946377-B1 COMBINATION THERAPIES BASED ON PD1 AND IL-17B INHIBITORS OREGA BIOTECH (FR) 2025-12-10 EP disclosed
US-20230045494-A1 COMBINATION THERAPIES BASED ON CTLA4 AND IL-17B INHIBITORS INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2023-02-09 US disclosed
EP-4110810-A1 COMBINATION THERAPIES BASED ON CTLA4 AND IL-17B INHIBITORS Orega Biotech (FR) 2023-01-04 EP disclosed
US-20220281967-A1 NOVEL IL-17B ANTIBODIES INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2022-09-08 US disclosed
US-20220175815-A1 COMBINATION THERAPIES BASED ON PD1 AND IL-17B INHIBITORS INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2022-06-09 US disclosed
EP-3946377-A1 COMBINATION THERAPIES BASED ON PD1 AND IL-17B INHIBITORS Orega Biotech (FR) 2022-02-09 EP disclosed
WO-2020201442-A1 COMBINATION THERAPIES BASED ON PD1 AND IL-17B INHIBITORS OREGA BIOTECH (FR) 2020-10-08 WO disclosed
EP-2569335-B1 METHODS OF TREATING AND/OR PREVENTING CELL PROLIFERATION DISORDERS WITH IL-17 ANTAGONISTS OREGA BIOTECH (FR) 2018-08-22 EP disclosed
US-20170233468-A1 IL-17 ANTAGONIST ANTIBODIES OREGA BIOTECH (FR) 2017-08-17 US disclosed
EP-1708751-A4 METHODS OF KILLING TUMOR CELLS BY TARGETING INTERNAL ANTIGENS EXPOSED ON APOPTOTIC TUMOR CELLS VACCINEX INC (US) 2007-11-07 EP disclosed
CN-1913921-A Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells VACCINEX INC (US) 2007-02-14 CN disclosed
EP-1708751-A2 METHODS OF KILLING TUMOR CELLS BY TARGETING INTERNAL ANTIGENS EXPOSED ON APOPTOTIC TUMOR CELLS Vaccinex, Inc. (US) 2006-10-11 EP disclosed
US-20050158323-A1 Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells VACCINEX, INC. (US) 2005-07-21 US disclosed
WO-2005055936-A2 METHODS OF KILLING TUMOR CELLS BY TARGETING INTERNAL ANTIGENS EXPOSED ON APOPTOTIC TUMOR CELLS VACCINEX, INC. (US) 2005-06-23 WO disclosed
US-20030114379-A1 Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (MPIF-1) HUMAN GENOME SCIENCES, INC. 2003-06-19 US disclosed
US-6495129-B1 Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3) HUMAN GENOME SCIENCES, INC. 2002-12-17 US disclosed
WO-2001026676-A9 METHODS OF TREATING OR PREVENTING CELL, TISSUE, AND ORGAN DAMAGE USING HUMAN MYELOID PROGENITOR INHIBITORY FACTOR-1 (MPIF-1) HUMAN GENOME SCIENCES INC (US) 2002-11-07 WO disclosed
EP-1225911-A1 METHODS OF TREATING OR PREVENTING CELL, TISSUE, AND ORGAN DAMAGE USING HUMAN MYELOID PROGENITOR INHIBITORY FACTOR-1 (MPIF-1) Human Genome Sciences (US) 2002-07-31 EP disclosed
WO-2001026676-A1 METHODS OF TREATING OR PREVENTING CELL, TISSUE, AND ORGAN DAMAGE USING HUMAN MYELOID PROGENITOR INHIBITORY FACTOR-1 (MPIF-1) HUMAN GENOME SCIENCES, INC. (US) 2001-04-19 WO disclosed